Titre :

First-line treatment of double- and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study.

Auteur(s) :

Laude, M. C. [Auteur]
Lebras, L. [Auteur]
Sesques, P. [Auteur]
Ghesquieres, H. [Auteur]
Favre, S. [Auteur]
Bouabdallah, K. [Auteur]
Croizier, C. [Auteur]
Guieze, R. [Auteur]
La Rochelle, L. D. [Auteur]
Gyan, E. [Auteur]
Chin, R. [Auteur]
Aurran-Schleinitz, T. [Auteur]
Marouf, A. [Auteur]
Deau-Fischer, B. [Auteur]
Coppo, P. [Auteur]
Malot, S. [Auteur]
Roussel, X. [Auteur]
Chauchet, A. [Auteur]
Schwarz, M. [Auteur]
Bescond, C. [Auteur]
Lamy De La Chapelle, T. [Auteur]
Bussot, L. [Auteur]
Carras, S. [Auteur]
Burlet, B. [Auteur]
Rossi, C. [Auteur]
Daniel, A. [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Subtil, F. [Auteur]
Michallet, A. S. [Auteur]

Titre de la revue :

American Journal of Hematology

Nom court de la revue :

Am J Hematol

Numéro :

96

Pagination :

302-311

Éditeur :

Wiley

Date de publication :

2020-12-16

ISSN :

1096-8652

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Historically, double or triple hit lymphoma (DHL and THL) have poor outcomes with conventional chemotherapy, but there is currently no guideline. We report the French experience in managing DHL and THL in first line using ...
Lire la suite >Historically, double or triple hit lymphoma (DHL and THL) have poor outcomes with conventional chemotherapy, but there is currently no guideline. We report the French experience in managing DHL and THL in first line using collective data on both survival and tolerance. All consecutive patients with newly diagnosis of large B-cell lymphoma with MYC, BCL2, and/or BCL6 rearrangements, as determined by FISH between January 2013 and April 2019 were included. Based on the eligibility criteria, 160 patients were selected among the 184 patients identified. With a median follow-up of 32 months, 2- and 4-year progression free survival (PFS) rates were 40% and 28% with R-CHOP compared with 57% and 52% with intensive chemotherapy (P = .063). There was no difference in overall survival (OS). For advanced stages, PFS was significantly longer with intensive chemotherapy than with R-CHOP (P = .029). There was no impact of autologous stem cell transplantation among patient in remission. For patients with central nervous system (CNS) involvement, the 2-year PFS and OS rate was 21% and 39%, vs 57% and 75% without CNS disease (P = .007 and P < .001). By multivariate analysis, elevated IPI score and CNS disease were strongly and independently associated with a poorer survival, whereas treatment was not significantly associated with OS. This is the largest series reporting the treatment of DHL and THL in Europe. The PFS was significantly longer with an intensive regimen for advanced stage, but no difference in OS, supporting the need for a prospective randomized trial.Lire moins >

Langue :

Anglais

Audience :

Internationale

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Date de dépôt :

2023-05-25T03:21:40Z
2023-09-20T08:58:58Z